Haili Bio-Technology to restructure, adjust acquisition price for Shaanxi Ruisheng

Shanghai Hile Bio-Technology Co., Ltd. will hold its first extraordinary general meeting of shareholders on October 9, 2025, to approve several key proposals. These include abolishing the Supervisory Board, with its functions transferring to the Board of Directors' Audit Committee, and changing the company's registered address and business scope.

Additionally, the company will seek approval for an adjustment to the transaction price of its acquisition of 55% equity in Shaanxi Ruisheng Bio-Technology Co., Ltd. The original acquisition price of CNY 935 million will be reduced to CNY 535.7 million. This adjustment follows a decline in Ruisheng Bio-Technology's performance due to increased industry competition and changes in tax preferential policies.

Consequently, Meilun Management Co., Ltd. will refund CNY 399.3 million, representing the difference in the adjusted transaction price. Furthermore, the net profit commitment for 2025 and 2026 for Ruisheng Bio-Technology will be revised to CNY 5 million and CNY 5.8 million, respectively, after deducting non-recurring gains and losses.